Utility of Single versus Tandem Autotransplants for Advanced Testes/Germ Cell Cancer: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 7, 2007, Pages 778-789

  Lazarus, Hillard M ^a   Stiff, Patrick J ^b   Carreras, Jeanette ^c   Logan, Brent R ^c   Akard, Luke ^d   Bolwell, Brian J ^e   Childs, Richard W ^f   Gale, Robert Peter ^g   Klein, John P ^c   Lill, Michael C ^h   Pérez, Waleska S ^c   Stadtmauer, Edward A ⁱ   Rizzo, J Douglas ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Indiana Blood and Marrow Transplantation   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f National Institute of Aging   (United States)

^g Center for Advanced Studies in Leukemia   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Germ cell cancer; Tandem autotransplant; Testis cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PLATINUM; THIOTEPA; VINBLASTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; AUTOTRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; ORCHIECTOMY; OVERALL SURVIVAL; PROBABILITY; PROGNOSIS; RECURRENCE RISK; SURVIVAL TIME; TESTIS CANCER;

ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TESTICULAR NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS;

EID: 34250208443     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.02.013     Document Type: Article

References (33)

1. Einhorn E.H. Testicular cancer: an oncological success story. Clin Cancer Res 3 (1997) 2630-2632
2. Sonneveld D.J., Hoekstra H.J., van der Graaf W.T., et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91 (2001) 1304-1315
3. Loehrer Sr. P.J., Gonin R., Nichols C.R., et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16 (1998) 2500-2504
4. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15 (1997) 594-603
5. Hartmann J.T., Nichols C.R., Droz J.P., et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 13 (2002) 1017-1028
6. Nichols C.R., Williams S.D., Loehrer P.J., et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9 (1991) 1163-1172
7. de Wit R., Stoter G., Sleijfer D.T., et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71 (1995) 1311-1314
8. Kaye S.B., Mead G.M., Fossa S., et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16 (1998) 692-701
9. Motzer R.J., Mazumdar M., Bajorin D.F., et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15 (1997) 2546-2552
10. Decatris M.P., Wilkinson P.M., Welch R.S., et al. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol 11 (2000) 427-434
11. Broun E.R., Nichols C.R., Turns M., et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 73 (1994) 1716-1720
12. Bhatia S., Abonour R., Porcu P., et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18 (2000) 3346-3351
13. Beyer J., Kramar A., Mandanas R., et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14 (1996) 2638-2645
14. Broun E.R., Nichols C.R., Gize G., et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 79 (1997) 1605-1610
15. Motzer R.J., Mazumdar M., Bosl G.J., et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14 (1996) 1098-1105
16. Vaena D.A., Abonour R., and Einhorn L.H. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 21 (2003) 4100-4104
17. Statistics NCfH. National Hospital Discharge Survey for 1990 and 1991, in Branch HCS. Hyattsville, MD: U. S. Department of Health and Human Services, Public Health Service, Centers for Disease Control.
18. Graves E.J. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1989. Vital Health Stat 13 (1991) 1-236
19. Curtis R.E., Rowlings P.A., Deeg H.J., et al. Solid cancers after bone marrow transplantation. N Engl J Med 336 (1997) 897-904
20. Silberman G., Crosse M.G., Peterson E.A., et al. Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med 331 (1994) 1063-1067
21. Kaplan E. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
22. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
23. Rosenbaum P., and Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983) 41-55
24. Rosenbaum P., and Rubin D. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79 (1984) 516-524
25. Andersen P.K., Klein J.P., and Zhang M.J. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med 18 (1999) 1489-1500
26. Mead G.M. International consensus prognostic classification of metastatic germ cell tumours treated with cisplatinum based chemotherapy: final report of the International Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol (1995)
27. Droz J.P., Pico J.L., Ghosn M., et al. Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J Cancer 27 (1991) 831-835
28. Schmoll H.J., Kollmannberger C., Metzner B., et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the german testicular cancer study group. J Clin Oncol 21 (2003) 4083-4091
29. Nichols C.R., Tricot G., Williams S.D., et al. Dose-intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7 (1989) 932-939
30. Nichols C.R., Andersen J., Lazarus H.M., et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 10 (1992) 558-563
31. Pico J.L., Rosti G., Kramar A., et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16 (2005) 1152-1159
32. Motzer R.J., and Sheinfeld S. Poor-risk testicular cancer and high-dose chemotherapy. J Clin Oncol 21 (2003) 4073-4074
33. Kollmannsberger C., Beyer J., Liersch R., et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 22 (2004) 108-114